BANGALORE: Bharat Biotech International Limited (BBIL), has announced the launch of Biohib, the first indigenously developed and manufactured haemophilus influenza type B (hib) vaccine in India and comvac 4-hb, a tetravalent combination vaccine.

An official release from BBIL on Monday stated: ‘Biohib is a safe and affordable vaccine that offer complete protection against hib infection.

Biohib is a conjugate vaccine that has proven its safety and efficacy in multi-centric clinical trials.’

While other Indian manufacturers had imported conjugation and manufacturing technologies from Europe and the USA, the scientific manufacturing and product development teams at Bharat biotech have completely developed all processes required to manufacture bio hib in-house, the release said.

The company had made investments to the tune of several million dollars over the past four years into its R&D capabilities and manufacturing facilities to enable the development and manufacture of biohib vaccine.

The comvac4-hb and Biohib enable the deployment of a combination pentavalent vaccine in a single injection, the release said.